The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
The Chemours CompanyNYSE: CC
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 33.7% from a year ago
Cash & equivalents stood at $671M at the end of Q2 FY2026, up 33.7% from a year earlier and up 19.2% from the prior quarter. Over 3 fiscal years it compounded at -15.2% a year.
Context
- Cash & equivalents amounted to 9.4% of total assets at the end of Q2 FY2026, up 2.7 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +33.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 672M USD
- Year-over-year change
- -5.8%
- 4-year CAGR
- -17.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 672M | -5.8% |
| FY2024 | 2024-12-31 | 713M | -40.7% |
| FY2023 | 2023-12-31 | 1.2B | +9.2% |
| FY2022 | 2022-12-31 | 1.1B | -24.1% |
| FY2021 | 2021-12-31 | 1.45B | — |
Cash & Equivalents vs competitors
How CC compares with its peers on the latest reported figures
- CC's Jun 2026 cash & equivalents of $671M is the 6th highest of the 19 companies compared; the peer median is $237.45M.
- Its year-over-year change of +33.7% is the 5th highest of 19, against a peer median of -2.8%.
- Cash & equivalents amounts to 9.4% of total assets for CC, versus a peer median of 5.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $4.9B | +2.3% | -2.4% | 5.5% | |
| Sep 2026 | $3.23B | +80.9% | +17.0% | 9.3% | |
| Sep 2026 | $1.76B | -8.5% | +6.9% | 9.2% | |
| Jun 2026 | $1.52B | -2.6% | +25.3% | 6.7% | |
| Sep 2026 | $1.33B | -28.2% | -11.9% | 3.2% | |
| Jun 2026 | $671M | +33.7% | -15.2% | 9.4% | |
| Jun 2026 | $633M | +0.8% | +0.3% | 8.2% | |
| Jun 2026 | $569M | -30.3% | +6.9% | 2.3% | |
| Jun 2026 | $440M | +112.6% | -30.7% | 9.6% | |
| Jun 2026 | $250M | +4.6% | +7.8% | 6.3% | |
| Sep 2026 | $224.9M | -62.2% | +33.1% | 3.8% | |
| Sep 2026 | $167.01M | -2.9% | -0.2% | 5.7% | |
| Mar 2026 | $162.6M | +27.6% | +21.1% | 13.0% | |
| Aug 2026 | $97.23M | -20.6% | +10.3% | 1.8% | |
| Jun 2026 | $82.78M | -41.2% | +37.0% | 2.6% | |
| Mar 2026 | $52M | +38.7% | -0.1% | 2.7% | |
| Sep 2026 | $34.07M | +91.1% | +35.2% | 1.9% | |
| Jun 2026 | $31.02M | -45.3% | +20.4% | 1.3% | |
| Mar 2026 | $22.37M | -77.0% | -33.6% | 12.5% | |
| Peer median (excluding CC) | $237.45M | -2.8% | +7.4% | 5.6% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.45B | 1.1B | 1.2B | 713M | 672M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 720M | 626M | 610M | 770M | 679M |
| Inventory | 1.1B | 1.4B | 1.35B | 1.47B | 1.57B |
| Other Current Assets | 0 | 82M | 705M | 71M | 81M |
| Total Current Assets | 3.35B | 3.21B | 3.84B | 3.03B | 3B |
| Property, Plant & Equipment (Net) | 3.38B | 3.41B | 3.48B | 3.44B | 3.35B |
| Goodwill | 102M | 102M | 102M | 46M | 46M |
| Intangible Assets | 6M | 13M | 3M | 3M | 2M |
| Long-term Investments | 169M | 175M | 158M | 152M | 160M |
| Tax Assets | 171M | 152M | 303M | 291M | 254M |
| Other Non-current Assets | 376M | 573M | 374M | 556M | 570M |
| Total Non-current Assets | 4.21B | 4.43B | 4.42B | 4.49B | 4.38B |
| Total Assets | 7.55B | 7.64B | 8.25B | 7.52B | 7.38B |
| Account Payables | 1.14B | 1.21B | 1.13B | 1.12B | 929M |
| Short-term Debt | 25M | 43M | 51M | 54M | 104M |
| Tax Payables | 64M | 42M | 28M | 44M | 0 |
| Deferred Revenue | 3M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 440M | 325M | 1.13B | 554M | 547M |
| Total Current Liabilities | 1.86B | 1.89B | 2.49B | 1.8B | 1.69B |
| Long-term Debt | 3.72B | 3.59B | 3.94B | 4.02B | 4.26B |
| Deferred Tax Liabilities | 49M | 61M | 44M | 35M | 37M |
| Deferred Revenue (Non-current) | 2M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 656M | 793M | 789M | 824M | 927M |
| Total Non-current Liabilities | 4.61B | 4.64B | 5.03B | 5.11B | 5.45B |
| Total Liabilities | 6.47B | 6.53B | 7.51B | 6.91B | 7.13B |
| Common Stock | 2M | 2M | 2M | 2M | 2M |
| Retained Earnings | 1.75B | 2.17B | 1.78B | 1.72B | 1.22B |
| Accumulated OCI | (364M) | (343M) | (274M) | (367M) | (244M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1M | 0 | 2M | 1M | 1M |
| Total Equity | 1.08B | 1.11B | 739M | 605M | 251M |
| Total Debt | 3.99B | 3.88B | 4.3B | 4.36B | 4.59B |
| Net Debt | 2.54B | 2.78B | 3.1B | 3.64B | 3.91B |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.